tbuckley/cabot-search huggingface dataset:
Sedentary Behavior and Public Health: Integrating the Evidence and Identifying Potential Solutions
Authors: Neville Owen, Genevieve N. Healy, Paddy C. Dempsey, Jo Salmon, Anna Timperio, Bronwyn K. Clark, Ana D. Goode, Harriet Koorts, Nicola D. Ridgers, Nyssa T. Hadgraft, Gavin Lambert, Elizabeth G. Eakin, Bronwyn A. Kingwell, David W. Dunstan
Journal: Annual Review of Public Health (2020)

In developed and developing countries, social, economic, and environmental transitions have led to physical inactivity and large amounts of time spent sitting. Research is now unraveling the adverse public health consequences of too much sitting. We describe improvements in device-based measurement that are providing new insights into sedentary behavior and health. We consider the implications of research linking evidence from epidemiology and behavioral science with mechanistic insights into the underlying biology of sitting time. Such evidence has led to new sedentary behavior guidelines and initiatives. We highlight ways that this emerging knowledge base can inform public health strategy: First, we consider epidemiologic and experimental evidence on the health consequences of sedentary behavior; second, we describe solutions-focused research from initiatives in workplaces and schools. To inform a broad public health strategy, researchers need to pursue evidence-informed collaborations with occupational health, education, and other sectors.
Prognostic Significance of Epidermal Growth Factor Receptor Overexpression and Chromosome 7 Polysomy in Clear Cell Renal Cell Carcinoma
Authors: F. Lumachi, D. Santeufemia, F. Pili, S.M. M. Basso, G. Lo Re, G. Miolo, G.B. Chiara, M. Ermani, S. Tumolo, P. Rocca Cossu
Journal: Annals of Oncology (2012)
Conservative Sensitivity Analyses of Progression-Free Survival (PFS) of Trabectedin Plus Pegylated Liposomal Doxorubicin (PLD) Vs. Pld Alone in Patients with Relapsed Ovarian Cancer: Ova-301 Study
Authors: I. Romero, E. Pujade-Lauraine, A. Tanovic, J. Gómez García, A.M. Poveda
Journal: Annals of Oncology (2012)
Efficacy and Safety of Sunitinib in Patients with Non-Clear Cell Renal Cell Carcinoma
Authors: J.-L. Lee, J.-H. Ahn, S.H. Park, H.Y. Lim, S.H. Lee, T.-M. Kim, Y.-M. Cho, C. Song, J.H. Hong, C.-S. Kim, H. Ahn
Journal: Annals of Oncology (2012)
Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment
Authors: Naykky Singh Ospina, Nicole M Iñiguez-Ariza, M Regina Castro
Journal: BMJ (2020)

ABSTRACT Thyroid nodules are extremely common and can be detected by sensitive imaging in more than 60% of the general population. They are often identified in patients without symptoms who are undergoing evaluation for other medical complaints. Indiscriminate evaluation of thyroid nodules with thyroid biopsy could cause a harmful epidemic of diagnoses of thyroid cancer, but inadequate selection of thyroid nodules for biopsy can lead to missed diagnoses of clinically relevant thyroid cancer. Recent clinical guidelines advocate a more conservative approach in the evaluation of thyroid nodules based on risk assessment for thyroid cancer, as determined by clinical and ultrasound features to guide the need for biopsy. Moreover, newer evidence suggests that for patients with indeterminate thyroid biopsy results, a combined assessment including the initial ultrasound risk stratification or other ancillary testing (molecular markers, second opinion on thyroid cytology) can further clarify the risk of thyroid cancer and the management strategies. This review summarizes the clinical importance of adequate evaluation of thyroid nodules, focuses on the clinical evidence for diagnostic tests that can clarify the risk of thyroid cancer, and highlights the importance of considering the patient’s values and preferences when deciding on management strategies in the setting of uncertainty about the risk of thyroid cancer.
Tivozanib Pharmacokinetic (PK)/Pharmacodynamic (PD) Analysis of Blood Pressure (BP) and Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2) in Patients with Advanced Renal Cell Carcinoma (RCC)
Authors: D. Nosov, R.J. Motzer, J. Loewy, L. Hodge, B. Esteves, A. Berkenblit, W. Yin, K. Dykstra, T.E. Hutson, M. Cotreau
Journal: Annals of Oncology (2012)
Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry
Authors: Alan K.Y. Teoh, Helen E. Jo, Daniel C. Chambers, Karen Symons, Eugene H. Walters, Nicole S. Goh, Ian Glaspole, Wendy Cooper, Paul Reynolds, Yuben Moodley, Tamera J. Corte
Journal: European Respiratory Journal (2020)

<b>Blood monocytes have been recently proposed as a potential prognostic marker for IPF. Data from the Australian IPF registry have shown that elevated monocytes, neutrophils and total leukocytes significantly predict poorer survival in IPF patients.</b>http://bit.ly/38GP7f0
Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation
Authors: Wing Hing Wong, Sima Bhatt, Kathryn Trinkaus, Iskra Pusic, Kevin Elliott, Nitin Mahajan, Fei Wan, Galen E. Switzer, Dennis L. Confer, John DiPersio, Michael A. Pulsipher, Nirali N. Shah, Jennifer Sees, Amelia Bystry, Jamie R. Blundell, Bronwen E. Shaw, Todd E. Druley
Journal: Science Translational Medicine (2020)

Donor hematopoietic clones with pathogenic mutations engraft and persist in unrelated hematopoietic stem cell transplant recipients.
Prognostic Factors Influencing the Selection of Bevacizumab Combined With Chemotherapy in Patients With HER2-Negative Metastatic Breast Cancer in Routine Clinical Practice. Oncosur-Avalox: Observational Cross-Sectional Study
Authors: L. Manso, R. Perez-Carrion, J.I. Chacon Lopez-Muniz, A. García Palomo, E. Galve Calvo, R.M. Llorente, J. Casinello, G. Catalán, C. Llorca, C. Grávalos
Journal: Annals of Oncology (2012)
Home-Based Zoledronic Acid (ZOL) Infusion Therapy in Patients with Solid Tumours: Compliance and Patient-Nurse Satisfaction
Authors: T. Lebret, J. Mouysset, A. Lortholary, C. El Kouri, L. Bastit, M. Ktiouet, K. Slimane, X. Muracciole, S. Guérif
Journal: Annals of Oncology (2012)
A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma
Authors: Hailong Ma, Hanyue Chang, Wenyi Yang, Yusheng Lu, Jingzhou Hu, Shufang Jin
Journal: Molecular Cancer (2020)

Abstract Background Interferon alpha (IFNα) is a well-established regulator of immunosuppression in head and neck squamous cell carcinoma (HNSCC), while the role of long noncoding RNAs (lncRNAs) in immunosuppression remains largely unknown. Methods Differentially expressed lncRNAs were screened under IFNα stimulation using lncRNA sequencing. The role and mechanism of lncRNA in immunosuppression were investigated in HNSCC in vitro and in vivo. Results We identified a novel IFNα-induced upregulated lncRNA, lncMX1–215, in HNSCC. LncMX1–215 was primarily located in the cell nucleus. Ectopic expression of lncMX1–215 markedly inhibited expression of the IFNα-induced, immunosuppression-related molecules programmed cell death 1 ligand 1 (PD-L1) and galectin-9, and vice versa. Subsequently, histone deacetylase (HDAC) inhibitors promoted the expression of PD-L1 and galectin-9. Binding sites for H3K27 acetylation were found on PD-L1 and galectin-9 promoters. Mechanistically, we found that lncMX1–215 directly interacted with GCN5, a known H3K27 acetylase, to interrupt its binding to H3K27 acetylation. Clinically, negative correlations between lncMX1–215 and PD-L1 and galectin-9 expression were observed. Finally, overexpression of lncMX1–215 suppressed HNSCC proliferation and metastasis capacity in vitro and in vivo. Conclusions Our results suggest that lncMX1–215 negatively regulates immunosuppression by interrupting GCN5/H3K27ac binding in HNSCC, thus providing novel insights into immune checkpoint blockade treatment.
P-0107 Gemcitabine and Cisplatin Combined with Regional Hyperthermia as Second-Line Treatment in Patients with Gemcitabine-Refractory Advanced Pancreatic Cancer
Authors: Katharina Lechner, Frank Berger, Nelli Dieterle, Sultan Abdel-Rahman, Christoph Salat, Rolf Issels
Journal: Annals of Oncology (2012)
Denosumab in Patients with Metastatic Prostate Cancer Previously Treated with Denosumab or Zoledronic Acid: 2-Year Open-Label Extension Phase Results from the Pivotal Phase 3 Study
Authors: K. Fizazi, J.E. Brown, M. Carducci, N.D. Shore, P. Sieber, F. Kueppers, L. Karsh, R. Wei, C. Goessl
Journal: Annals of Oncology (2012)
Prognostic Value of Circulating Tumor Cells in Early Breast Cancer Patients Detected by RT-PCR of Mamaglobin
Authors: A.M. Hilal, H.M. Elzawahrey, A.A. Abd Elwahab, M.N. Abdelhafez, M.M. Moneer, A.D. Darwish
Journal: Annals of Oncology (2012)
Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis
Authors: Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, Manisha Palta
Journal: Journal of the National Comprehensive Cancer Network (2020)

Background: Adjuvant chemotherapy (AC) after chemoradiation (CRT) and surgery for locoregionally advanced rectal cancer (LARC) is a standard of care in the United States. This study examined the role, optimal regimen, and duration of AC using data from the largest integrated health system in the United States. Patients and Methods: Using the Veterans Affairs Central Cancer Registry, patients with stage II–III rectal cancer diagnosed in 2001 through 2011 who received neoadjuvant CRT and surgery with or without AC were identified. Kaplan-Meier analysis, log-rank tests, and propensity score (PS) adjustment analysis were used to assess survival. Results: A total of 866 patients were identified; 417 received AC and 449 did not (observation [OBS] group). Median follow-up was 109 months. Median disease-specific survival (DSS) was not reached. Six-year DSS was 73.7%; 79.5% for the AC group versus 68.0% for the OBS group. PS-matched analysis for DSS favored AC ( P =.0002). Median overall survival (OS) was 90.8 months. Six-year OS was 56.7%; 64.3% for AC versus 49.6% for OBS. In PS-matched analysis, median OS was 117.4 months for AC and 74.3 months for OBS ( P &lt;.0001). A DSS advantage was seen when comparing ≥4 months with &lt;4 months of AC ( P =.023). No difference in DSS or OS was seen with single-agent versus multiagent AC. Conclusions: In this population of patients with LARC treated with neoadjuvant CRT and surgery, OS and DSS were improved among those treated with AC versus OBS. DSS benefits were seen with ≥4 months of AC. No additional benefit was observed with multiagent therapy. In the absence of phase III data, these findings support the use of AC for LARC.
Erlotinib as Frontline Treatment for Elderly Patients (P) with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC): Ggcp044/09 Study
Authors: J.L. Firvida, S. Vazquez, J. Casal, M. Alonso, S. Varela, M.J. Villanueva, F.J. Afonso, O. Fernandez, C. Areses, B. Campos
Journal: Annals of Oncology (2012)
Impact of EGFR Mutation Status on Clinical Benefit from BIBW 2992 in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) Progressing After Chemotherapy (CTX) and Erlotinib (E) or Gefitinib (G) – A Single Center Experience
Authors: J. Köhler, K. Worm, T.C. Gauler, M. Hoiczyk, D. Theegarten, W. Eberhardt, J. Hense, F. Breitenbuecher, K.W. Schmid, M. Schuler
Journal: Annals of Oncology (2012)
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
Authors: S. Ugurel, D. Schadendorf, K. Horny, A. Sucker, S. Schramm, J. Utikal, C. Pföhler, R. Herbst, B. Schilling, C. Blank, J.C. Becker, A. Paschen, L. Zimmer, E. Livingstone, P.A. Horn, V. Rebmann
Journal: Annals of Oncology (2020)
Envisioning a Better U.S. Health Care System for All: Health Care Delivery and Payment System Reforms
Authors: Shari M. Erickson, Brian Outland, Suzanne Joy, Brooke Rockwern, Josh Serchen, Ryan D. Mire, Jason M. Goldman
Journal: Annals of Internal Medicine (2020)

The American College of Physicians (ACP) has long advocated for universal access to high-quality health care in the United States. Yet, it is essential that the U.S. health system goes beyond ensuring coverage, efficient delivery systems, and affordability. Fundamental restructuring of payment policies and delivery systems is required to achieve a health care system that puts patients' interests first and supports physicians and their care teams to deliver high-value, patient- and family-centered care. The ACP calls for reform of U.S. payment, delivery, and information technology systems to achieve this vision. The ACP's recommendations include increased investment in primary care; alignment of financial incentives to achieve better patient outcomes, lower costs, reduce inequities in health care, and facilitate team-based care; freeing patients and physicians of inefficient administrative and billing tasks and documentation requirements; and development of health information technologies that enhance the patient-physician relationship.
Nanostructured toxins for the selective destruction of drug-resistant human CXCR4+ colorectal cancer stem cells
Authors: Naroa Serna, Patricia Álamo, Prashanthi Ramesh, Daria Vinokurova, Laura Sánchez-García, Ugutz Unzueta, Alberto Gallardo, María Virtudes Céspedes, Esther Vázquez, Antonio Villaverde, Ramón Mangues, Jan Paul Medema
Journal: Journal of Controlled Release (2020)
Abstract 3395: TargetTranslator: Big data identifies non-canonical targets for high risk neuroblastoma
Authors: Elin Almstedt, Caroline Wärn, Ramy Elgendy, Neda Hekmati, Emil Rosén, Ida Larsson, Rebecka Jörnsten, Cecilia Crona, Sven Nelander
Journal: Cancer Research (2019)

Abstract Despite the many advances in the molecular characterization of neuroblastoma, effective treatments for high-risk patients are currently lacking. Using publically available data, integrated computational analysis offers new opportunities to uncover druggable subgroups. In the TargetTranslator project, we have combined state-of-the-art Big Data techniques to identify new targets in high-risk subgroups of neuroblastoma. Starting with clinical or genomic risk factors, TargetTranslator builds a consensus molecular signature across cohorts. This signature is scored against a massive amount of data from (i) childhood tumor biobanks (TARGET, R2), (ii) drug profiling data from cancer cell models (NIH-LINCS), and (iii) drug targets and pathways (STITCH, STRING, MSIGDB). As output, the system provides ranked lists of compounds, molecular targets and pathways for each risk factor, as well as an aggregated probability score. In a proof-of-concept study, we used TargetTranslator to recommend treatments for high-risk neuroblastoma subgroups, including COG high-risk, MYCN amplification, 11q deletion, and signatures of differentiation and ALK activation. Depending on risk group stratification, we detected between 21 and 680 substances (p&amp;lt;0.001), most of which were strongly associated to approximately 10 key targets. In addition to confirming a key role for the PI3K/mTOR and MAPK pathways, we detected high scoring compounds in non-canonical pathways, including neurotransmission, GLI/SMO, ROCK and PKA. Experimental validation of 11 predicted drugs in patient-derived neuroblastoma lines confirmed our signatures and reduced viability. We also identified four new compounds that significantly (p&amp;lt;0.05) suppressed MYCN protein levels (ROCK inhibitor fasudil, CNR2 agonist GW405833, CDK inhibitor AZD5438, lovastatin) at concentrations non-toxic in zebrafish embryos. By integrating data from patients, drugs, and drug-protein networks, we establish a new computational pipeline that predicts protein targets in specific patient subgroups. The TargetTranslator introduces a way to bridge drug effects with patient data and will be available as a user-friendly web tool on www.targettranslator.org in 2018. Citation Format: Elin Almstedt, Caroline Wärn, Ramy Elgendy, Neda Hekmati, Emil Rosén, Ida Larsson, Rebecka Jörnsten, Cecilia Crona, Sven Nelander. TargetTranslator: Big data identifies non-canonical targets for high risk neuroblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3395.
A Randomized, Double-Blind, Phase (PH) III Study of Folfiri Plus Ramucirumab (RAM) or Placebo (PL) in Patients (Patients) with Metastatic Colorectal Carcinoma (MCRC) Progressed During or Following 1st-Line Therapy with Bevacizumab (BEV), Oxaliplatin (OXALI), and a Fluoropyrimidine (FP) (RAISE) (NCT01183780).
Authors: K. Yamazaki, A. Ohtsu, T. Yoshino, M. Yoshida, A. Grothey, J. T.abernero, P. Rougier, S. Ballal, H. Crane, N. Yoshizuka, F. Nasroulah, M.D. Rutstein
Journal: Annals of Oncology (2012)
Phase II Study of S-1 Plus Leucovorin (New 1 Week Treatment Regimen Followed by 1 Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China
Authors: H. Baba, J. Li, R. Xu, J. Xu, T. Denda, K. Ikejiri, L. Shen, Y. Toh, K. Shimada, T. Kato, K. Sakai, A. Matsuyama, H. Mishima, J. Wang
Journal: Annals of Oncology (2012)
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
Authors: Paul K. Paik, Rachel K. Kim, Linda Ahn, Andrew J. Plodkowski, Ai Ni, Mark T.A. Donoghue, Philip Jonsson, Miguel Villalona-Calero, Kenneth Ng, Daniel McFarland, John J. Fiore, Afsheen Iqbal, Juliana Eng, Mark G. Kris, Charles M. Rudin
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Gemcitabine and albumin-bound paclitaxel (ABP) exhibit synergistic antitumor efficacy, with ABP serving to increase the intratumoral gemcitabine concentration. Both drugs are active in squamous cell lung cancers (SQCLC) and are conventional partners for carboplatin. We hypothesized that combining gemcitabine and ABP would enhance the antitumor activity in patients with advanced SQCLCs. Patients and Methods: This was a Simon two-stage, open-label, single-arm, multicenter phase II study that enrolled patients between August 1, 2015 and June 1, 2018. We enrolled 37 patients with chemotherapy-naïve, PD-L1 low/unknown advanced stage IV SQCLC. Patients were administered weekly intravenous gemcitabine (1,000 mg/m2) plus ABP (100 mg/m2) in a 3-week on, 1-week off schedule during stage I and a 2-week on, 1-week off schedule in stage II. The primary endpoint was best objective response rate (ORR). Next-generation sequencing by MSK-IMPACT was used to calculate tumor mutation burden and genome doubling and assess somatic variants for correlations with efficacy. Results: Thirty-two patients were evaluable for response assessment. The study satisfied its primary endpoint, with confirmed partial responses in 18 of 32 patients and a complete response in 1 patient [ORR 59%; 95% confidence interval (CI), 42%–74%]. Median progression-free survival (PFS), a secondary endpoint, was 7.5 (95% CI, 6.7–10.5) months. There were no unexpected toxicities. Conclusions: Gemcitabine plus ABP was a safe, tolerable, and effective first-line therapy for patients with chemotherapy-naïve SQCLCs, with an ORR and median PFS substantially higher than carboplatin doublet regimens and efficacy comparable with carboplatin plus taxane plus pembrolizumab.
Nested Case Control Study of Proteomic Biomarkers for Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Treated With Erlotinib
Authors: N. Katakami, S. Atagi, H. Yoshioka, M. Fukuoka, A. Ogiwara, M. Imai, M. Ueda, S. Matsui
Journal: Annals of Oncology (2012)
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction
Authors: Jordana B Cohen, Sarah J Schrauben, Lei Zhao, Michael D Basso, Mary Ellen Cvijic, Zhuyin Li, Melissa Yarde, Zhaoqing Wang, Priyanka T Bhattacharya, Diana A Chirinos, Stuart Prenner, Payman Zamani, Dietmar A Seiffert, Bruce D Car, David A Gordon, Kenneth Margulies, Thomas Cappola, Julio A Chirinos
Journal: JACC Heart Failure (2020)
Burden of Skeletal-Related Events (SRES) in Patients (PTS) with Solid Tumors: Results of the Stars Observational Study in the US vs EU
Authors: I. Duran, A. Mahmood, H. Hoefeler, H. Ghazal, D. Lueftner, M. Fink, A. Bahl, G. Hechmati, R. Wei, C. Atchison
Journal: Annals of Oncology (2012)
Telephonic Consultations during Outpatient Chemotherapy at National Cancer Center Hospital
Authors: J. Hashimoto, S. Kondo, J. Tomomatsu, S. Iwasa, H. Horinouchi, E. Konno, H. Fukada, M. Motonaga, H. Harashima, R. Udagawa, A. Umeta, M. Nagase, M. Asanabe, K. Tamura, Y. Fujiwara
Journal: Annals of Oncology (2012)
Phase II Study of Erlotinib for Previously Treated Non-Small Cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutation: Central Japan Lung Study Group (CJLSG) 0903 Trial
Authors: M. Morise, H. Taniguchi, H. Saka, J. Shindoh, R. Suzuki, E. Kojima, T. Hase, M. Kondo, H. Saito, Y. Hasegawa
Journal: Annals of Oncology (2012)
Pneumonia in China: lack of information raises concerns among Hong Kong health workers
Authors: Jane Parry
Journal: BMJ (2020)

An outbreak of pneumonia of unknown cause in Wuhan, China, has prompted authorities in neighbouring Hong Kong, Macau, and Taiwan to step up border surveillance, amid fears that it could signal the emergence of a new and serious threat to public health.

On 5 January local, provincial, and national health commissions reported a cluster of 59 reported cases centred around the South China Seafood Wholesale Market in Wuhan, a city of 11 million people and the capital of Hubei province. They had already ruled out known influenza viruses and the two coronaviruses known to cause severe acute respiratory illness (SARS) and Middle East respiratory syndrome.

The limited information that has been released by mainland Chinese authorities is causing unease among the general population and healthcare workers in Hong Kong. The city has a strong collective memory of the SARS outbreak in 2003, which …
P2.16 Estrogen Receptors Alpha and Beta as Targets for Non-Small Cell Lung Cancer Hormonal Therapy
Authors: T.A. Bogush, E.A. Dudko, A.S. Shaturova, M.V. Tikhomirov, E.A. Bogush, B.E. Polotsky, S.A. Tjulandin, M.I. Davydov
Journal: Annals of Oncology (2012)